Previous close | 0.3900 |
Open | 0.4000 |
Bid | 0.3959 x 100 |
Ask | 0.4048 x 100 |
Day's range | 0.3901 - 0.4099 |
52-week range | 0.3700 - 4.2000 |
Volume | |
Avg. volume | 2,728,368 |
Market cap | 5.64M |
Beta (5Y monthly) | 1.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On Monday, Soligenix Inc (NASDAQ:SNGX) received an FDA orphan drug designation for the active ingredient in MarVax, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for the prevention and post-exposure prophylaxis against MARV infection. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, i
Key Insights Soligenix will host its Annual General Meeting on 15th of December Total pay for CEO Christopher Schaber...